Specialties & Topics
- Arthritis/Rheumatic Disease
- Breast Cancer
- GERD/Peptic Ulcers
An ongoing dialogue on HIV/AIDS, infectious diseases,
April 10th, 2008
Needed: Something Better than “HAART”
I think we all have pet peeves, and so I’ll confess one of mine: I hate the term “HAART.”
(I work with someone, by the way, who hates the term “viral load,” preferring “virus load.” Go figure.)
Standing for “highly active antiretroviral therapy,” HAART first surfaced in the mid-1990s in order to distinguish potent anti-HIV treatment from the older, not-so-active form of antiretroviral therapy that preceded it. Writers often will use the phrases “era of HAART” or “advent of HAART,” both of which sound to me like essays on Dutch history.
But HAART has never been very precise — what exactly does it mean?
The vagueness is illustrated by a quick Google search of “define: HAART,” which gives no fewer than 9 definitions, including:
- “A term for aggressive anti-HIV treatment” (Really? Isn’t it standard-of-care treatment? It’s not “aggressive” if everyone is doing it.)
- “Combination anti-HIV therapy, usually involving a protease inhibitor …” (Nope, not quite — EFV or NVP + 2 NRTIs is the most common initial treatment worldwide, so, in fact, HIV therapy does not “usually” involve a PI.)
- “Treatment [of HIV] with a very potent drug cocktail” (Uh-oh, another pet peeve alert — that never-to-die use of “cocktail” to describe HIV treatment, something the lay press still adores. Even worse, “potent cocktail”? A Mai Tai at Trader Vic’s, anyone?)
- “A combination of protease inhibitors taken with reverse transcriptase inhibitors” (Again, just wrong, though I suppose ritonavir-boosted PIs are a “combination of protease inhibitors,” so partial credit.)
Several years ago, when the imprecision of HAART first started to get under my skin, I suggested to one of our fellows that she do a review of published HIV clinical studies to collect the various definitions in common use at the time.
She looked at me like I was out of my mind — okay, more like “get a life.” I still think it would be an interesting paper, but how would one do such a review — searching PubMed for HAART yields a mere 11, 937 results.
The problem is that I don’t have a ready alternative. The D:A:D folks tried “cART” several years ago, standing for combination antiretroviral therapy (kind of liked that one), but I don’t see the abbreviation in their latest paper; I confess to using “ART” (antiretroviral therapy) when abbreviating HIV treatment; in AIDS Clinical Care, our Executive Editor prefers “potent combination antiretroviral therapy,” all 15 syllables worth.
None of these terms gets it quite right, I’m afraid.
Any ideas? Or should I just give up? Help!
Paul E. Sax, MD
Learn more about HIV and ID Observations.
- Mystifying Abbreviations on Daily Medical Rounds (46)
- Should Doctors Still Be Allowed to Wear White Coats? You Decide (43)
- Are ID Doctors the Worst Dressed Specialists? (39)
- A Ridiculously Long Post: How EHRs Expose Unspoken Hierarchies Within Medicine — Or Maybe Are Just Bad (34)
- Which Infectious Diseases Do We Fear Too Much? Which Not Enough? (33)
- A Ridiculously Long Post: How EHRs Expose Unspoken Hierarchies Within Medicine — Or Maybe Are Just Bad
- Lots of College Graduations ID Link-O-Rama
- Zika, Baseball, and Waiting for a “New Normal”
- Why ID/HIV Specialists Rank Last in MD Salaries
- Drug Prior Authorizations Are a Very Blunt Tool for Cost Containment — And They’re Annoying
Subscribe to HIV and ID Observations via Email
- Absence of Transmitted Resistance to HIV Integrase Inhibitors in Swiss Cohort
- New Insights into the Effects of Broadly Neutralizing Antibodies Against HIV
- Passive Immunization Against Monkey HIV Produces Encouraging Results
- Addiction Therapy Initiated Rarely for Injecting Drug Users with Infectious Endocarditis
- Characteristics of Acute HIV-1 Infection (FREE)
Physician's First WatchToday's breaking medical news
- Abacavir AIDS aids clinical care antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff CROI cure darunavir dolutegravir efavirenz elvitegravir etravirine FDA HCV hepatitis C HIV HIV testing ID Learning Unit Infectious Diseases influenza lamivudine Link-o-Rama lyme disease Massachusetts MRSA Patient Care PEP Policy PrEP prevention primary care raltegravir Research resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir vaccination